Cytomedix Inc. (CMXI) Submits 510(k) to FDA for Bone Marrow Aspirate Concentrate Indication for Angel System
9/1/2011 10:08:55 AM
GAITHERSBURG, Md., Sept. 1, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announced today the recent submission of a 510(k) to the U.S. Food and Drug Administration ("FDA") for use of the Angel® Whole Blood Separation System for processing a bone marrow aspirate. The expanded indication includes processing a mixture of blood and bone marrow, a rich source of stem cells.
comments powered by